Latest Period
Q2 2026
Security Snapshot
RECURSION PHARMACEUTICALS, INC. - COMMON STOCK (RXRX) Institutional Ownership
CUSIP: 75629V104
13F Institutional Holders and Ownership History from Q1 2019 to Q2 2026
Institutions Reporting
338
Shares (Excl. Options)
361,221,627
Price
$3.67
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- RXRX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 361,221,627
- Total 13F value
- $1,325,471,057
- Portfolio coverage rank
- 0%
- Share change
- +25,657,551
- Value change
- +$98,134,374
- Number of holders
- 338
- Shares outstanding
- 525,850,455
- SEC-reported price per share
- $2.97
- Insider filing price
- $2.97
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RXRX - RECURSION PHARMACEUTICALS, INC. - COMMON STOCK is tracked under CUSIP 75629V104.
- 338 institutions reported positions in Q2 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 331 to 338 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,032,087,949 to $1,325,471,057.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 338 institutions filings for Q2 2026.
Security key
75629V104
Latest holder period
Q2 2026
13F holders
338
13D/G owners
8
CIK / CUSIP context first
Open Q2 2026 holders
RXRX full holder history
RECURSION PHARMACEUTICALS, INC. SEC filings
RECURSION PHARMACEUTICALS, INC. company facts
RECURSION PHARMACEUTICALS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75629V104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
RXRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 8.5% | +19% | $163,467,690 | +$24,661,695 | 44,541,605 | +18% | BlackRock, Inc. | 30 Jun 2026 |
| ARK Investment Management LLC | 7.2% | -15% | $152,625,941 | +$20,329,177 | 37,316,856 | +15% | ARK Investment Management LLC | 31 Dec 2025 |
| STATE STREET CORP | 6.6% | $123,553,823 | 34,706,130 | STATE STREET CORPORATION | 30 Jun 2026 | |||
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6% | $111,674,615 | 31,369,274 | Vanguard Portfolio Management | 30 Jun 2026 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1% | $95,209,099 | 26,744,129 | Vanguard Capital Management | 30 Jun 2026 | |||
| BAILLIE GIFFORD & CO | 4.6% | $97,239,635 | 23,774,972 | BAILLIE GIFFORD & CO | 31 Dec 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 2% | $44,187,549 | 7,725,096 | RA Capital Management, L.P. | 31 Dec 2024 | |||
| Kim Yohan | 5.9% | $1,530,100 | 267,500 | Yohan Kim | 04 Apr 2025 |
As of 30 Jun 2026, 338 institutional investors reported holding 361,221,627 shares of RECURSION PHARMACEUTICALS, INC. - COMMON STOCK (RXRX). This represents 69% of the company’s total 525,850,455 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
60%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9.6% | 50,304,691 | +16% | 0% | $184,618,217 |
| ARK Investment Management LLC | 7.9% | 41,337,632 | +2.8% | 0.99% | $151,709,111 |
| STATE STREET CORP | 6.6% | 34,706,130 | +22% | 0% | $127,371,497 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.9% | 31,131,599 | +37% | 0.01% | $114,252,968 |
| BAILLIE GIFFORD & CO | 4.5% | 23,487,907 | -0.79% | 0.08% | $86,200,618 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 22,765,940 | +2.3% | 0% | $83,551,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6% | 13,819,135 | +13% | 0% | $50,724,628 |
| SOFTBANK GROUP CORP. | 2.6% | 13,636,515 | 0% | 0.28% | $50,046,010 |
| MIC Capital Management UK LLP | 1.8% | 9,644,033 | +0% | 9% | $35,393,601 |
| UBS Group AG | 1.7% | 8,947,102 | +75% | 0.01% | $32,835,865 |
| NORGES BANK | 1.3% | 6,833,534 | 0% | $25,079,070 | |
| Data Collective IV GP, LLC | 1.1% | 5,941,120 | 0% | 28% | $21,803,910 |
| Sumitomo Mitsui Trust Group, Inc. | 1% | 5,511,687 | +1.7% | 0.01% | $20,227,891 |
| Amova Asset Management Americas, Inc. | 1% | 5,511,687 | +1.7% | 0.26% | $20,227,891 |
| NORTHERN TRUST CORP | 0.9% | 4,758,236 | +20% | 0% | $17,462,727 |
| MARSHALL WACE, LLP | 0.9% | 4,714,577 | +64% | 0.01% | $17,302,499 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.79% | 4,138,286 | +8.7% | 0% | $15,187,510 |
| DCVC Opportunity Fund II GP, LLC | 0.75% | 3,951,141 | 0% | 84% | $14,500,687 |
| GOLDMAN SACHS GROUP INC | 0.75% | 3,917,858 | -35% | 0% | $14,378,538 |
| VANGUARD FIDUCIARY TRUST CO | 0.66% | 3,470,558 | -1.3% | 0% | $12,736,948 |
| TWO SIGMA INVESTMENTS, LP | 0.64% | 3,353,658 | -18% | 0.01% | $12,307,925 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.63% | 3,292,128 | -22% | 0.01% | $12,082,110 |
| FIRST TRUST ADVISORS LP | 0.58% | 3,041,829 | +17% | 0.01% | $11,163,512 |
| MORGAN STANLEY | 0.52% | 2,743,498 | +26% | 0% | $10,068,638 |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 0.5% | 2,604,317 | +1.8% | 0.61% | $9,557,843 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
30
Latest
Q2 2026
Rows shown
1-25 of 30
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 361,221,627 | $1,325,471,057 | +$98,134,374 | $3.67 | 338 |
| 2026 Q1 | 336,160,522 | $1,032,087,949 | +$24,653,196 | $3.07 | 331 |
| 2025 Q4 | 324,266,763 | $1,326,312,624 | +$25,282,966 | $4.09 | 333 |
| 2025 Q3 | 324,190,091 | $1,581,950,465 | +$66,787,219 | $4.88 | 321 |
| 2025 Q2 | 310,182,949 | $1,569,493,304 | +$26,510,398 | $5.06 | 329 |
| 2025 Q1 | 304,244,163 | $1,609,644,830 | -$29,277,099 | $5.29 | 330 |
| 2024 Q4 | 304,544,141 | $2,058,776,356 | +$268,240,445 | $6.76 | 310 |
| 2024 Q3 | 264,392,743 | $1,743,289,324 | +$54,064,157 | $6.59 | 262 |
| 2024 Q2 | 251,836,128 | $1,888,574,788 | +$298,622,706 | $7.50 | 264 |
| 2024 Q1 | 212,714,397 | $2,120,552,518 | +$62,304,334 | $9.97 | 242 |
| 2023 Q4 | 206,501,532 | $2,035,976,922 | +$306,507,294 | $9.86 | 194 |
| 2023 Q3 | 152,228,034 | $1,164,429,792 | +$189,175,887 | $7.65 | 189 |
| 2023 Q2 | 127,547,789 | $952,749,699 | +$12,757,431 | $7.47 | 155 |
| 2023 Q1 | 126,153,704 | $841,388,403 | +$14,595,249 | $6.67 | 157 |
| 2022 Q4 | 123,786,379 | $954,397,559 | +$134,707,594 | $7.71 | 144 |
| 2022 Q3 | 113,749,582 | $1,210,251,991 | +$75,709,491 | $10.64 | 141 |
| 2022 Q2 | 106,463,853 | $861,094,172 | +$96,496,440 | $8.14 | 130 |
| 2022 Q1 | 95,043,699 | $680,250,380 | -$12,978,444 | $7.16 | 124 |
| 2021 Q4 | 94,346,907 | $1,616,473,942 | +$295,962,917 | $17.13 | 122 |
| 2021 Q3 | 54,909,739 | $1,262,978,377 | +$181,552,159 | $23.01 | 82 |
| 2021 Q2 | 46,974,230 | $1,714,334,294 | +$1,714,333,294 | $36.50 | 75 |
| 2021 Q1 | 30 | $1,000 | $33.33 | 1 | |
| 2020 Q4 | 30 | $1,000 | $33.33 | 1 | |
| 2020 Q3 | 30 | $1,000 | $33.33 | 1 | |
| 2020 Q2 | 30 | $1,000 | $33.33 | 1 |